AMRX: Amneal Pharmaceuticals, Inc. Stock

by  •  • Comments Off on AMRX: Amneal Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,322.44
Enterprise Value ($M) 4,814.77
Book Value ($M) -59.39
Book Value / Share -0.19
Price / Book -39.16
NCAV ($M) -1,914.19
NCAV / Share -6.11
Price / NCAV -1.21

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.00
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.84
Current Ratio 1.40

Balance Sheet (mrq) ($M)
Current Assets 1,510.45
Assets 3,365.25
Liabilities 3,424.64
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,793.96
Operating Income 350.84
Net Income -116.89
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 295.10
Cash from Investing -63.00
Cash from Financing -211.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-30 13G Vanguard Group Inc 5.02 15.54
03-17 13D/A Patel Tushar Bhikhubhai 15.70 -9.33
02-10 13G/A UBS Group AG
01-23 13D/A Patel Dipan 7.70 -11.43
11-14 13G/A Mahesh Akram 8.80 -11.61
10-31 13D/A Patel Chirag K. 7.10 0.00
2024-04-24 13G/A Fosun International Ltd 3.00 -50.02

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 373,126 1,567,112 23.81
2025-05-08 233,970 1,501,067 15.59
2025-05-07 256,692 1,586,256 16.18
2025-05-06 650,621 2,017,567 32.25
2025-05-05 553,957 1,957,253 28.30

(click for more detail)

Similar Companies
AMGN – Amgen Inc. AMLX – Amylyx Pharmaceuticals, Inc.
AMPH – Amphastar Pharmaceuticals, Inc. ANAB – AnaptysBio, Inc.
ANNX – Annexon, Inc.


Financial data and stock pages provided by
Fintel.io